The development of new molecular therapies targeting particular abnormalities such as mutations in the <i>EGFR</i> (<i>Epidermal Growth Factor Receptor</i>) gene or <i>ROS1</i> or <i>ALK</i> genes rearrangements resolved in novel strategies in advanced NSCLC management. Here, ALK is linked to non-small cell lung carcinoma.